CIA
BIIB icon

Concurrent Investment Advisors’s Biogen BIIB Stock Holding History

Concurrent Investment Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407K Sell
2,222
-2,154
-49% -$397K ﹤0.01% 1315
2025
Q4 		$770K Buy
4,376
+2,804
+178% +$458K 0.01% 947
2025
Q3 		$220K Buy
+1,572
New +$212K ﹤0.01% 1303
2024
Q4 		– Sell
-3,340
Closed -$647K – 1135
2024
Q3 		$647K Sell
3,340
-46
-1% -$9.62K 0.02% 563
2024
Q2 		$785K Buy
3,386
+389
+13% +$84.5K 0.03% 489
2024
Q1 		$646K Buy
2,997
+1,567
+110% +$367K 0.03% 479
2023
Q4 		$370K Buy
+1,430
New +$351K 0.02% 576

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Concurrent Investment Advisors's BIIB Position: Q1 2026 in Review

Concurrent Investment Advisors reduced its Biogen (BIIB) stake by 49% in Q1 2026, selling an estimated $397K and leaving 2,222 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Concurrent Investment Advisors first reported a position in BIIB in Q4 2023 and has held it in 7 quarters since. The position peaked at $785K in Q2 2024. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Concurrent Investment Advisors held 2,222 shares of Biogen worth $407K as of Q1 2026.
  • Concurrent Investment Advisors sold 2,154 Biogen shares in Q1 2026, an estimated $397K.
  • Biogen made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q1 2026, its #1315 holding.
  • Concurrent Investment Advisors first reported a position in Biogen in Q4 2023 and has held it in 7 quarters since.
  • Concurrent Investment Advisors's Biogen position peaked at $785K in Q2 2024.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.